Analyzing the evolution of the selected topology revealed a non-canonical architecture of the MAPK pathway in the A-375 melanoma cell line and a Sorafenib-mediated effect: while Sorafenib is a BRAF kinase and VEGFR-2 inhibitor and, thereby, prevents phosphorylation of MEK1/2 [36], the observed phosphorylation profile of ERK1/2 was not consistently inhibited. Here, MAPK3 is linked to melanoma.